SAB Biotherapeutics 2026 Q3 Earnings Call
Review the key takeaways and the transcript of this earnings call.
- SAB Bio ended the 3rd quarter of 2026 with $205 million in cash, cash equivalents, and investment securities as of September 30th, 2026, including $13.4 million in gross proceeds from warrant exercises.
- R&D expenses were $18.1 million in the 3rd quarter of 2026, compared with $9 million in the same period in 2025; G&A expenses were $7.8 million, compared with $3.7 million.
- Other income was $3.6 million in the 3rd quarter of 2026, compared with $58.1 million in the same period in 2025, primarily reflecting the change in fair value of warrant liabilities recognized in 2025.
- Net loss was $22.3 million in the 3rd quarter of 2026, compared with net income of $45.4 million in the same period in 2025.
- The adult and adolescent cohorts in the SABEguard study are fully enrolled and closed for screening, and the data monitoring committee approved the final step down to children ages 5 to 11 in September.
- The FDA granted fast-track designation to SAB-142 in October for treatment of new-onset stage 3 type 1 diabetes.
STOCKNOW INSIGHTS
Continue with outlook and guidance.
Log in to unlock executive comments and Q&A highlights.
Log in for the full summaryStockNow uses AI to translate and summarize earnings calls. Accuracy and completeness are not guaranteed.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Good morning, and welcome to SAB Bio's conference call to discuss third quarter 2026 financial results and business updates. Listeners are invited to review the full text of the forward-looking statements from this morning's quarterly earnings press release. Company management may provide projections during this call, and actual results could differ materially due to several factors, including those outlined in the company's latest filings with the SEC. Currently, all participants are in a listen-only mode. Following management's remarks, we will open the call for questions. This call is being webcast live and can be accessed on the investors section of SAB Bio's website at ir.sab.bio, where a replay will be available. I'll now turn the call over to Samuel Reich, Chief Executive Officer of SAB Bio.
Thank you, operator. Good morning, and thank you to everyone joining us for our third quarter 2026 earnings call. I'm joined today by Lucy To, our Chief Financial Officer, who will review the third quarter financial results. I'm also joined by Eddie Sullivan, our Co-Founder and President, and Alexandra Kropotova, our Chief Medical Officer. As we begin November, we recognize Diabetes Awareness Month and focus attention on the millions of people living with type 1 diabetes. We remain committed to advancing new medicines with the potential to change the course of the disease and improve the lives of those affected. That focus continues to drive our work at SAB Bio, and we're pleased to have you with us today to review the progress we made during the third quarter.
We continue to execute on our priorities for SAB-142, with strong momentum in SAFEGUARD enrollment and the FDA granting Fast Track designation to SAB-142 for the treatment of new-onset Stage 3 type 1 diabetes. For context, SAB-142 is a fully human anti-thymocyte immunoglobulin designed to preserve insulin-producing beta cells in order to slow disease progression in autoimmune type 1 diabetes. It was developed using our proprietary Tc Bovine platform, which allows us to generate fully human multi-specific antibodies without the need for human donors. Because SAB-142 is fully human, it has the potential to overcome key limitations of non-human approaches and enable safe redosing over the long term. We believe SAB-142 represents an opportunity to help people with type 1 diabetes redefine what a Stage 3 diagnosis can mean.
SAB-142 is currently being evaluated in two clinical trials, the registrational Phase IIb SAFEGUARD study for those newly diagnosed with Stage 3 T1D, and the investigator-led Phase III PRISE study for people up to two years from a Stage 3 T1D diagnosis. Let's start with an enrollment update for SAFEGUARD. The performance of our clinical team this quarter has been exemplary. In September, the study's Data Monitoring Committee approved the final step-down to children ages five to 11, helping to further accelerate enrollment. We continue to see strong interest in SAFEGUARD from both patients and investigators, and we're excited to share that the adult and adolescent cohorts are now fully enrolled and closed for screening. With that, we are reaffirming our guidance to complete enrollment of SAFEGUARD in Q4, with top-line data expected in the second half of 2027.
Building on that progress, the PRISE study expects to dose the first patient this quarter. There are seven clinical sites planned across the U.S., Europe, and the U.K. PRISE is an important extension of the SAB-142 clinical program, as it would potentially allow a future label expansion for SAB-142 to T1D patients up to two years from a Stage 3 diagnosis. As a reminder, PRISE is an investigator-led study supported by a grant from Breakthrough T1D and co-funded by SAB Bio. We are grateful to Breakthrough T1D for its support and to Dr. Michael Haller at the University of Florida, who serves as the study's principal investigator. We also want to recognize Dr. Chantal Mathieu at UZ Leuven and Dr. Timothy Tree at King's College London as co-principal investigators for their important contribution to the study.
Beyond our clinical progress, we reached an important regulatory milestone in October when the FDA granted Fast Track designation to SAB-142 for the treatment of new-onset Stage 3 type 1 diabetes. This designation is intended to facilitate the development and expedite the review of therapies for serious conditions where there is an an unmet medical need, with the goal of bringing important new treatments to patients earlier. For SAB-142, this designation gives the program some serious aura, and importantly, it provides valuable procedural benefits as we advance our program. These include opportunities for more frequent meetings and written communications with the FDA, eligibility for rolling review of a future BLA, and potential eligibility for Priority Review if the applicable criteria are met.
While Fast Track designation does not change the FDA's standards for approval or ensure that SAB-142 will ultimately be approved, we believe the benefits are meaningful as we move toward top-line data. We will continue to work closely with the FDA as we advance the SAB-142 clinical program, and we believe this designation represents meaningful progress toward our goal of bringing SAB-142 to people living with type 1 diabetes as quickly as possible. With that, I will hand the call over to Lucy To, our Chief Financial Officer, for a recap of our third quarter financials.
Thanks, Sam. We ended the third quarter with $205 million in cash equivalents, and investment securities as of September 30, 2026. We maintain a strong cash position and project that our existing cash balance will fund our operations through 2028. This total includes $13.4 million in gross proceeds received in the third quarter from the exercise of our previously issued enrollment and data release warrants from our July 2025 PIPE. R&D expenses were $18.1 million for the third quarter of 2026, compared to $9 million for the same period in 2025. The increase is primarily driven by ongoing clinical trial costs and related headcount to support the advancement of SAB-142 through the registrational SAFEGUARD study. R&D expenses include non-cash stock-based compensation expense of $3.9 million for the third quarter of 2026, compared to $0.5 million for the same period in 2025.
G&A expenses were $7.8 million for the third quarter of 2026, compared to $3.7 million for the same period in 2025. The increase is primarily driven by personnel-related costs, including non-cash stock-based compensation. G&A expenses include non-cash stock-based compensation expense of $3.6 million for the third quarter of 2026, compared to $0.3 million for the same period in 2025. Other income was $3.6 million for the third quarter of 2026, compared to $58.1 million for the same period in 2025. The decrease primarily reflects the change in fair value of warrant liabilities recognized in 2025. As a result, net loss was $22.3 million for the third quarter of 2026, compared to the net income of $45.4 million for the same period in 2025.
Overall, we reaffirm our position to support SAB-142's clinical development in the SAFEGUARD and PRISE studies through key milestones while preparing for commercial readiness for SAB-142. With that, I can turn it back over to Sam for closing remarks before we open the call for questions.
Thanks, Lucy. We're pleased with the progress we made during the third quarter and enter the final months of the year with a clear focus, completing enrollment in SAFEGUARD and continuing to advance SAB-142 toward top-line data. We're incredibly grateful to our team, our investigators and clinical collaborators, the patients and families participating in SAFEGUARD, and the broader diabetes community. Their commitment and engagement continue to drive our work and reinforce the importance of developing new therapies for people living with type 1 diabetes. As we look to 2027, we're excited to move toward top-line data from SAFEGUARD while continuing to build the capabilities and infrastructure needed to support SAB-142 over the long term. We believe SAB-142 has the potential to meaningfully change the treatment of type 1 diabetes, and we are focused on delivering on that promise.
We look forward to sharing our progress as we continue advancing SAB-142 across our clinical programs and executing on our strategy. With that, we're ready to take any questions.
Thank you. We will now be conducting a question-and-answer session. If you would like to ask a question, please press star one on your telephone keypad. A confirmation tone will indicate your line is in the question queue. You may press star two if you would like to remove your question from the queue. For participants using speaker equipment, it may be necessary to pick up your handset before pressing the star keys. One moment, please, while we pull for questions. The first question is from Michael Yee from UBS. Please go ahead. Hey, guys.
Good morning. Congrats on the progress on enrollment. As we think about the data ahead next year, could you sort of comment or reiterate your framing of expectations on that result in terms of C-peptide and A1C and how important each of those are to hit for differentiation to TZIELD? Secondly, given that TZIELD now has a new stage 3 indication, while we've been talking with different docs, what are you hearing out there? What are you seeing? Is that perhaps a pretty good indication of what the opportunity could be, although it's still early there?
Thank you. Thanks, Mike. I'll answer the second part first and then hand it to Alexandra to answer the first question.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Log in to unlock every statement, the English original, and speaker-by-speaker history.
Log in for the full transcriptCall participants
12 people spoke on this call — only 2 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
